P.065 AVXS-101 gene-replacement therapy (GRT)) in presymptomatic spinal muscular atrophy (SMA): study update. (5th June 2019)

• Record Type: Journal Article
• Authors: Schultz, M; Swoboda, K; Farrar, M; McMillan, H; Parsons, J; Farrow, M; Ogrinc, FG; Feltner, DE; McGill, BE; Spector, SA; L'Italien, J; Sproule, DM; Strauss, KA
• Is Part Of: Canadian journal of neurological sciences. Volume 46(2019)Supplement 1
• Page Start: S31
• Page End: S32
• Publication Date: 2019-06-05
• Subjects: Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Electronic journals; 616.8
• DOI: 10.1017/cjn.2019.165
• Languages: English
• ISSNs: 0317-1671

Abstract

Abstract : Background: SMA is a neurodegenerative disease caused by biallelic deletion/mutation of SMN1 . Copies of a similar gene ( SMN2 ) modify disease severity. In a phase 1 study, SMN GRT onasemnogene abeparvovec (AVXS-101) improved outcomes of symptomatic SMA patients with two SMN2 copies (2x SMN2 ) dosed ≤6 months. Because motor neuron loss can be insidious and disease progression is rapid, early intervention is critical. This study evaluates AVXS-101 in presymptomatic SMA newborns.Methods: SPR1NT is a multicenter, open-label, phase 3 study enrolling ≥27 SMA patients with 2–3x SMN2 . Asymptomatic infants ≤6 weeks receive a one-time intravenous AVXS-101 infusion (1.1x1014 vg/kg). Safety and efficacy are assessed through study end (18 [2x SMN2 ] or 24 months [3x SMN2 ]). Primary outcomes: independent sitting for ≥30 seconds (18 months [2x SMN2 ]) or assisted standing (24 months [3x SMN2 ]).Results: From April–September 2018, 7 infants received AVXS-101 (4 female; 6 with 2x SMN2 ) at ages 8–37 days. Mean baseline CHOP-INTEND score was 41.7 (n=6), which increased by 6.8, 11.0, 18.0, and 22.5 points at day 14 (n=4), month 1 (n=3), 2 (n=3), and 3 (n=2). Updated data available at the time of the congress will be presented.Conclusions: Preliminary data from SPR1NT show rapid motor function improvements in presymptomatic SMA patients.